MONISTAT 3 COMBINATION PACK (PREFILLED)
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MONISTAT 3 COMBINATION PACK (PREFILLED) (MONISTAT 3 COMBINATION PACK (PREFILLED)).
Miconazole inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
| Metabolism | Primarily hepatic via oxidative metabolism; CYP3A4 involved; negligible systemic absorption after vaginal administration. |
| Excretion | Approximately 50% of absorbed dose excreted in feces via biliary elimination; <1% excreted unchanged in urine. Unabsorbed drug from vaginal administration is eliminated in vaginal discharge. |
| Half-life | Terminal elimination half-life is approximately 20-30 hours for miconazole after systemic absorption, reflecting slow elimination from deep tissue compartments. |
| Protein binding | Approximately 90-93% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 14 L/kg, indicating extensive tissue penetration and distribution into peripheral compartments. |
| Bioavailability | Vaginal administration results in minimal systemic absorption (approximately 1-2% of dose). |
| Onset of Action | Vaginal: Relief of symptoms typically begins within 24-72 hours after first dose. |
| Duration of Action | Therapeutic concentrations persist for up to 3 days after single vaginal application; clinical cure rates are established with 3-day regimen. |
| Molecular Weight | 416.13 |
Intravaginal administration of one applicator (200 mg miconazole nitrate) at bedtime for 3 consecutive days.
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Not recommended for children under 12 years of age. |
| Geriatric use | No specific dose adjustment; use with caution due to potential comorbidities. |
| 1st trimester | Topical miconazole is not associated with increased risk of major malformations; limited human data; animal studies show no teratogenicity at doses 1-2 times human dose. Avoid intravaginal use in first trimester unless essential. |
| 2nd trimester | Topical miconazole is considered safe for use in second trimester; systemic absorption minimal (<1.5%). Intravaginal use is acceptable. |
| 3rd trimester | Topical miconazole is considered safe in third trimester; no known fetal risk. Use as directed. |
Clinical note
Comprehensive clinical and safety monograph for MONISTAT 3 COMBINATION PACK (PREFILLED) (MONISTAT 3 COMBINATION PACK (PREFILLED)).
| Placental transfer | Minimal systemic absorption (<1.5%) after topical application; placental transfer is negligible. No data on fetal exposure after intravaginal use. |
| Breastfeeding | Miconazole is not absorbed systemically after topical application; minimal excretion into breast milk expected. Topical use on nipple/areola should be avoided to prevent infant ingestion. Intravaginal use is compatible with breastfeeding. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to miconazole or any componentKnown hypersensitivity to other azole antifungals
| Precautions | For vaginal use only, Do not use if abdominal pain, fever, or foul-smelling discharge present, May weaken latex condoms and diaphragms, Discontinue if hypersensitivity occurs |
| Food/Dietary | No clinically significant food interactions. Take with or without food. |
| Clinical Pearls | Miconazole nitrate is an imidazole antifungal used intravaginally for vulvovaginal candidiasis. The combination pack includes a 7-day cream for external use and 3 prefilled applicators for internal use. Advise patients to complete full course even if symptoms improve. Avoid use during menstruation; if menses begins, continue treatment. For pregnant patients, manual insertion preferred over applicator. Potential for vaginal burning or irritation; if severe, discontinue. May damage latex condoms and diaphragms; advise abstinence or barrier alternative for 5 days post-treatment. Monitor for hypersensitivity; contraindicated in known miconazole allergy. |
Loading safety data…
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | Miconazole (main ingredient) is an azole antifungal. Systemic absorption after vaginal application is minimal (approximately 1.4%). Available data from pregnant women are insufficient to determine a drug-associated risk of major birth defects or miscarriage. Animal studies with subcutaneous miconazole have shown embryotoxicity and fetotoxicity at doses toxic to the dam; no malformations were noted. First trimester: limited data, no definitive risk. Second and third trimesters: no evidence of fetal harm from topical/vaginal use. Overall risk is considered low due to minimal systemic absorption. |
| Fetal Monitoring | No specific monitoring is required beyond routine prenatal care. If used for systemic fungal infection (not typical for this product), monitor liver function tests and signs of hepatotoxicity. |
| Fertility Effects | No evidence of impairment of fertility in animal studies. Miconazole vaginal cream and suppositories are not known to affect human fertility. |
| Patient Advice | Use the prefilled applicator vaginally at bedtime for 3 consecutive nights. · Apply the external cream to the vulvar area twice daily for up to 7 days. · Complete the full treatment course even if symptoms resolve early. · Do not use tampons, douches, spermicides, or other vaginal products during treatment. · Avoid sexual intercourse during treatment; condoms and diaphragms may be weakened. · If pregnant, insert applicator manually instead of using the full applicator depth. · Report severe abdominal pain, fever, foul-smelling discharge, or worsening symptoms. · Do not use if you have a history of allergic reaction to miconazole or similar antifungals. · Discontinue if vaginal irritation or burning becomes bothersome. · If symptoms persist beyond 7 days, seek medical evaluation for alternative diagnosis. |